The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.
The study design belongs to a retrospective study, collecting information on patients with PTCL who were diagnosed and treated with chidamide as maintenance therapy at our center. The collected data includes age, gender, previous treatment regimens, results of auxiliary examinations (such as blood routine, biochemistry, bone marrow cytology, pathology, flow cytometry, NGS, etc.), as well as PET-CT images. The safety and efficacy of Chidemide as first-line maintenance therapy in PTCL will be analyzed.
Study Type
OBSERVATIONAL
Enrollment
200
This subset of patients received chidamide as first-line maintenance therapy.
Hematological Department, People's Hospital of Jiangsu Province
Nanjing, Jiangsu, China
RECRUITINGPFS
progression free survival
Time frame: 2 years
OS
overall survival
Time frame: 2 years
CR
complete remission
Time frame: 2 years
DOR
duration of remission
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.